Detalles de la búsqueda
1.
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 23(5): 625-635, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35405088
2.
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Breast Cancer Res
; 24(1): 58, 2022 09 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36056374
3.
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials.
Int J Cancer
; 148(10): 2614-2627, 2021 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33533487
4.
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial.
Int J Cancer
; 146(1): 262-271, 2020 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31162838
5.
A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA).
Anticancer Drugs
; 30(4): 394-401, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30875348
6.
Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer.
Breast Cancer Res Treat
; 149(1): 141-9, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25519041
7.
Functional and Radiologic Outcomes of Degenerative Versus Traumatic Full-Thickness Rotator Cuff Tears Involving the Supraspinatus Tendon.
Am J Sports Med
; 52(2): 441-450, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38259113
8.
Staging for Breast Cancer: A Comparison Between Old and New Approaches.
Cancer Diagn Progn
; 3(6): 673-677, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37927808
9.
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
J Clin Oncol
; 41(22): 3796-3804, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36809046
10.
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial.
Clin Cancer Res
; 29(4): 805-814, 2023 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36441798
11.
Hypofractionated Whole Breast Irradiation and Boost-IOERT in Early Stage Breast Cancer (HIOB): First Clinical Results of a Prospective Multicenter Trial (NCT01343459).
Cancers (Basel)
; 14(6)2022 Mar 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35326548
12.
Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis-Results from the Adjuvant SUCCESS A Trial.
Cancers (Basel)
; 14(16)2022 Aug 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36010945
13.
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.
J Clin Oncol
; 40(23): 2557-2567, 2022 08 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35404683
14.
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial.
Clin Cancer Res
; 28(22): 4995-5003, 2022 11 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35797219
15.
Identification and characterization of 12 microsatellite loci in Cnidium dubium (Apiaceae) using next-generation sequencing.
Am J Bot
; 98(5): e127-9, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21613179
16.
Smoking complicates the course of non-infectious uveitis.
Graefes Arch Clin Exp Ophthalmol
; 249(6): 903-7, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21207052
17.
The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials.
Breast
; 59: 58-66, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34166854
18.
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer.
Cancers (Basel)
; 13(19)2021 Sep 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34638369
19.
TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer.
Cancer Med
; 10(23): 8581-8594, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34779146
20.
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial.
J Immunother Cancer
; 9(5)2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33963012